Luspatercept Lowers the Transfusion Burden in Patients With Myelofibrosis-Associated Anemia
Aaron Gerds, MD discusses the results of a phase II BELIEVE study of luspatercept as treatment of patients with myelofibrosis-associated anemia.
Aaron Gerds, MD, assistant professor of Medicine, Cleveland Clinic - Taussig Cancer Center, discussed the results of a phase II BELIEVE study of luspatercept (Reblozyl) as treatment of patients with myelofibrosis-associated anemia.
Every cohort in the study had responses to treatment with luspatercept. Additionally, luspatercept successfully reduced the transfusion burden in 21.4% of the study subjects compared only 4.5% of those who received placebo, meeting the primary end point of the study.
Gerd notes, however, that responses were higher in patients who received ruxolitinib (Jakafi) along with the luspatercept.
<< View more content from the 2019 American Society of Hematology Annual Meeting
Need for Systemic Therapy Remains in Sarcoma
November 27th 2023In an interview with Targeted Oncology, Lisa B. Ercolano, MD, discussed the evolving treatment landscape for sarcomas and underscored the pivotal role of molecular profiling, while addressing the need for more efficacious systemic therapies.
Read More
Oh Discusses Goals of Treatment in Patients With Cytopenic Myelofibrosis
November 23rd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Stephen T. Oh, MD, PhD, discussed with participants when they would use pacritinib for patients with thrombocytopenia related to myelofibrosis.
Read More
Trials Support Use of Momelotinib After JAK Inhibition for Anemic MF
November 21st 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Salman Fazal, MD, discussed data from the SIMPLIFY-2 and MOMENTUM trials of momelotinib for patients with myelofibrosis. This is the second of 2 articles based on this event.
Read More
MANIFEST-2 Meets Primary End Point With Pelabresib Plus Ruxolitinib in MF
November 21st 2023Along with improvements shown for the primary and secondary end points of the phase 3 MANIFEST-2 trial in JAK inhibitor-naive patients with myelofibrosis, pelabresib plus ruxolitinib did not display any new safety signals.
Read More
BRUIN MCL-321 Trial Evaluates Pirtobrutinb Monotherapy in MCL
November 20th 2023In an interview with Targeted Oncology, Michael Wang, MD, discussed the rationale of the phase 3 study and how positive results from this trial may further shape the mantle cell lymphoma treatment landscape.
Read More
